Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy

Radiation Oncology

Hui-Qin Li¹  Yi-Chao Geng¹  Qing-Song Li¹  Bing Lu¹  Yin-Xiang Hu¹  Zhu Ma¹  Sheng-Fa Su¹  Wei-Wei Ouyang¹ 

[1] Department of Thoracic Oncology, Affiliated Hospital of Guiyang Medical College, and Guizhou Cancer Hospital, 1 Beijing Road West, Guizhou Guiyang, China

关键词: Chemotherapy;    Thoracic Radiotherapy;    Bone Metastases;    Non-small Cell Lung Cancer;   

Others  :  800921
DOI  :  10.1186/1748-717X-9-147

 received in 2014-03-02, accepted in 2014-06-21,  发布年份 2014

【 摘 要 】

Background

To evaluate the efficacy of three-dimensional radiotherapy for non-small cell lung cancer (NSCLC) patients with bone metastases.

Methods

Clinical data for 95 NSCLC patients with bone metastases were collected and prognostic factors were analyzed. All patients received radiation to their thoracic primary tumor and ≥2 cycles of chemotherapy.

Results

Of these 95 patients, 47 patients had only bone metastases and 48 had both bone metastases and other organ metastases. Univariate analysis showed that factors that statistically significantly contributed to patients having longer overall survival (OS) included receiving a radiation dose to the primary tumor ≥63 Gy, responding to treatment and receiving ≥4 cycles of chemotherapy (p = 0.001, p = 0.037 and p = 0.009, respectively). A radiation dose to the primary tumor ≥63 Gy remained significant for patients with bone metastases only as well as those with bone and other organ metastases when they were analyzed separately (p = 0.045 and p = 0.012, respectively). For patients with bone metastases only, those with T1-2 tumors had longer OS than those with T3-4 (p = 0.048); and patients who received ≥4 cycles chemotherapy compared with those who received <4 cycles had similar OS (p = 0.385). On multivariate analysis, only a radiation dose ≥63 Gy (p = 0.028) and having only bone metastases (p = 0.006) were independent prognostic factors for better OS.

Conclusions

A radiation dose to the primary tumor ≥63 Gy and having only bone metastases were associated with better OS in NSCLC patients with bone metastases. For patients with bone metastases only, besides radiation dose, T status was also correlated with OS, whereas the number of chemotherapy cycles was not. Therefore, aggressive thoracic radiation may play an important role in improving OS.

【 授权许可】

   
2014 Ouyang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
• [3]Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
• [4]Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R: Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol 2009, 4:1524-1529.
• [5]Li FH, Lu B, Fu HY, Han L, Li QS, Li HQ: Metastasis features of 546 patients with stage IV non-small cell lung cancer at first visit and the significance in radiotherapy. Chin J Radiat Oncol 2012, 2:122-125.
• [6]Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
• [7]Tsuya A, Kurata T, Tamura K, Fukuoka M: Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007, 57:229-232.
• [8]Su SF, Lu B, Zhang B, Hu YX, Ouyang WW, Li HQ, Wang G, Long JH: A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage IV non-small cell lung cancer (1)——survival and toxicity. Chin J Radiat Oncol 2011, 6:467-472.
• [9]Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z: Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis. Int J Radiat Oncol Biol Phys 2012, 84:e61-e67.
• [10]Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerda M, de la Mata MD, Zavala DG, Muñiz-Hernández S, de la Garza J: Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol 2011, 6:166. BioMed Central Full Text
• [11]Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
• [12]Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, Stefanescu M, Pham E, Socinski MA, Marks LB: The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2012, 84:e385-e392.
• [13]Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13:8-10.
• [14]Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G: Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg 2005, 11:401-404.
• [15]Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L: Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2011, 29:3825-3831.
• [16]Reinfuss M, Mucha-Malecka A, Walasek T, Blecharz P, Jakubowicz J, Skotnicki P, Kowalska T: Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity. Lung Cancer 2011, 71:344-349.
• [17]Tian J, Shi RH, Jiang T, Zeng ZC, Zhang X, Bai CX: Influential factor for the survival after radiotherapy for brain metastases from the pulmonary tumor in the 45 patients. China Oncology 2006, 16:310-312.
• [18]Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA: High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:324-333.